https://forbion.com/no/news-insights/news/catalym-doses-first-patient-in-phase-2b-trial-evaluating-visugromab-in-combination-with-chemoimmunotherapy-as-second-line-treatment-in-unresectablemetastatic-hepatocellular-carcinoma/
CatalYm Doses First Patient in Phase 2b Trial | Forbion
Study targets patients with unresectable or metastatic hepatocellular carcinoma who have progressed following first-line anti-PD-(L)1-based therapy
in phasedosesfirstpatienttrial
https://www.catalym.com/
Catalym – Catalyzing Immunotherapy
immunotherapy